2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Abstract Number: 2459

Epidemiologic Profile of Erectile Dysfunction in SLE: A Multi-Center Study in Latin American Patients
Abstract Number: 2460

Predictive Factors of Good Response to Conventional Dmards in Patients with Early Seronegative Rheumatoid Arthritis: Data from the Espoir Cohort
Abstract Number: 2461

Identifying Flare in Rheumatoid Arthritis: What Is the Threshold?
Abstract Number: 2462

Higher Number of Tender Than Swollen Joint Count Is Associated to Higher Patient Reported Outcomes and Composite Scores As Well As Reduced Probability of Obtaining Remission: Results from a One-Year Follow-up Study of Established RA Patients Starting Bdmards
Abstract Number: 2463

Association Between High Sodium Intake and Subclinical Atherosclerosis in Patients with Rheumatoid Arthritis
Abstract Number: 2464

Comparison of Disease Activity Score (DAS) 28-CRP to DAS28-ESR in Patients with Active Rheumatoid Arthritis
Abstract Number: 2465

Discordance Between Tender and Swollen Joint Count and Patient’s and Evaluator’s Global Assessment May Reduce Likelihood of Remission in Rheumatoid Arthritis
Abstract Number: 2466

Remission According to RAPID3 (routine assessment of patient index data 3) in Patients with Rheumatoid Arthritis: A Cross-Sectional 3 Center Study from Routine Care
Abstract Number: 2467

Validation of the FLARE Questionnaire for the Detection of a Disease Flare in Rheumatoid Arthritis
Abstract Number: 2468

Assessment of the American-English Version of the French FLARE in Rheumatoid Arthritis
Abstract Number: 2469

How Rheumatoid Arthritis Patients and Rheumatologists Communicate during Clinic Visits When a New DMARD Is Prescribed
Abstract Number: 2470

Treat to Target: Theoretical Agreement Vs Daily Applicability
Abstract Number: 2471

What Are the Reasons of Discrepancies Between Patients and Physicians in Their Perceptions of Rheumatoid Arthritis Disease Activity and What Is the Impact of This Discordance on Remission, Function and Structure at 1 Year?
Abstract Number: 2472

Early DAS28 Drop Is a Predictor for Clinical Response to Anti-TNF Agents in Patients with Rheumatoid Arthritis: An Observational Study of a Real Life Inception Cohort
Abstract Number: 2473

Concordance Between the Patient, Nurse and Physician Assessment of Clinical Outcomes in a Cohort of Rheumatoid Arthritis Patients Treated with Certolizumab Pegol

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].